Hypoactive Sexual Desire Disorder (HSDD) Treatment Market 2019-2027 – Credence Research | Industry Size, Share & Forecast

Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Is Expected To Expand At A CAGR of 5.2%

SAN JOSE, United States - August 14, 2019 /MarketersMedia/ —

The latest market report published by Credence Research, Inc. “Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis, 2019- 2027,” the global hypoactive sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.

Browse the full report Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis 2019 – 2027 at https://www.credenceresearch.com/report/hypoactive-sexual-desire-disorder-hsdd-treatment-market

Market Insights

Hypoactive sexual desire disorder (HSDD) is currently on a rise in adult women population manifested by low self confidence and less connected with their partners. Recent approval of Vyleesi will provide essential momentum for the HSDD market growth. Currently 2 drugs such as BP101 and Prasterone 6.5 mg vaginal insert are under phase 3 clinical trial are being investigated for its safety and efficacy for treatment of HSDD.

Hypoactive sexual desire disorder is the most common type of sexual dysfunction occurring in adult women worldwide manifested by lack of sex interest for a period of six months or more due to personal distress or fluctuating sex hormones during the menstrual cycle. Accurate diagnosis of the symptoms manifested in hypoactive sexual desire disorder (HSDD) is very critical to finalize the treatment regimen which is either psychotherapy or pharmacotherapy. The PLISSIT model (Permission, Limited Information, Specific Suggestions and Intensive Therapy) aids in initial screening of HSDD. Psychotherapy is suggested to patients showing positive response to counseling sessions with sex therapist.

Request Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Sample: https://www.credenceresearch.com/sample-request/59843

Pharmacotherapy comprises of buspirone and bupropion off label treatment for HSDD in women suffering with low libido associated with anxiety and depression. Testosterone transdermal patches are used as an off label treatment in premenopausal and postmenopausal women with HSDD. Flibanserin is currently the only drug approved by USFDA for treating HSDD in premenopausal women owing to its multifunctional serotonin agonist and antagonist pharmacodynamic profile.

North America is the largest regional segment in the hypoactive sexual desire disorder (HSDD) treatment market representing a market share of 38.5%. The chief attributing factors responsible for its supreme market growth are growing incidence of low libido in the female population owing to increasing stress in daily life and fluctuating sex hormones during the menstrual cycle. Domicile of key players such as AMAG Pharmaceutcials, Allergan, Plc., S1 Biopharma, Inc. and Sprout Pharmaceuticals, Inc. further propel the market growth in North America regional segment. Europe is placed in the second position with a market share of 32.4% primarily due to affordable reimbursement scenario for the medicines prescribed for the treatment of hypoactive sexual desire disorder (HSDD). Asia Pacific holding a market share of 15.2% will be growing at a rapid pace during the forecast period owing to rising prevalence of HSDD in working women population and developing healthcare infrastructure.

Pharmaceutical companies providing pharmacotherapy for treating hypoactive sexual desire disorder are AMAG Pharmaceutcials, Allergan, Plc., Ivix, LLX., EndoCeutics, Inc., Emotional Brain BV., S1 Biopharma, Inc. and Sprout Pharmaceutcials, Inc.

Key Market Movements:

Growing incidence of low sex drive in women population worldwide
Affordable reimbursement scenario for pharmacotherapy employed in the treatment of HSDD
Recent approval of Vyleesi and strong product pipeline will further propel the HSDD market growth during the forecast period

Request Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Sample: https://www.credenceresearch.com/sample-request/59843

TOC:

1. Preface...

2. Executive Summary...

3. Hypoactive Sexual Desire Disorder Treatment Market: Dynamics and Future Outlook...

Chapter 4. Global Hypoactive Sexual Desire Disorder Treatment Market, by Therapy
4.1. Overview
4.2. Buspirone
4.3. Bupropion
4.4. Testosterone
4.5. Flibanserin
4.6. Bremelanotide
4.7. Cognitive Behavior Therapy
4.8. Pipeline Analysis
4.8.1. Phase III Drug
4.8.1.1. Prasterone 6.5 mg Vaginal Insert
4.8.1.2. BP101

Chapter 5. Global Hypoactive Sexual Desire Disorder Treatment Market, by Geography
5.1. Overview
5.2. North America Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017 – 2027
5.2.1. North America Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.2.2. North America Hypoactive Sexual Desire Disorder Treatment Market, by Country, 2017 – 2027 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017– 2027
5.3.1. Europe Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.3.2. Europe Hypoactive Sexual Desire Disorder Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017 – 2027
5.4.1. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.4.2. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific...

Chapter 6. Company Profiles
6.1. AMAG Pharmaceuticals
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Allergan, Plc.
6.3. Ivix LLX
6.4. EndoCeutics, Inc.
6.5. Emotional Brain BV ...

Browse the full report Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis 2019 – 2027 at https://www.credenceresearch.com/report/hypoactive-sexual-desire-disorder-hsdd-treatment-market

About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
Phone: +18003618290
Website: https://www.credenceresearch.com

Source URL: https://marketersmedia.com/hypoactive-sexual-desire-disorder-hsdd-treatment-market-2019-2027-credence-research-industry-size-share-forecast/88908175

Source: MarketersMedia

Release ID: 88908175

More News From chillhype.com

Globes carpet kicks off with big sleeves and shades of pink

Jan 21, 2020

NEW YORK — Cynthia Erivo and Greta Gerwig rocked sparkling chokers as the Golden Globes red carpet kicked off Sunday, with Erivo in a hand-beaded custom Thom Browne gown and Gerwig in black and cream. Both went off-shoulder for the big night in Beverly Hills, California. Erivo, the “Harriet” star and fashion standout, said her dress includes designs of her favorite flower, the peony, at the hem and in her lining. The short-sleeve gown, Erivo told E!, took 800 hours. A huge blue stone dropped from her short necklace. Shades of pink had an early trend moment on Kirsten Dunst...

Close call in majors can lead to some major recovery time

Jan 21, 2020

KAPALUA, Hawaii — J.B. Holmes played only two rounds in four months leading into the new year. He expected some rust at Kapalua, and it showed when he managed only two birdies in his opening round of 78. He can recover from that, especially in a 34-man field with no cut in the Sentry Tournament of Champions. Far more difficult was getting over his shot to win a major. For two days at Royal Portrush, Holmes played some of his best golf and shared the 36-hole lead. Even after Shane Lowry began to pull away with a 63 in the...

No. 7 Oregon beats No. 11 Wisconsin 28-27 in Rose Bowl

Jan 21, 2020

PASADENA, Calif. — Justin Herbert scored his third rushing touchdown of the 106th Rose Bowl on a thrilling 30-yard run with 7:41 to play Wednesday night, and No. 7 Oregon held off No. 11 Wisconsin 28-27 to win its third straight trip to the Granddaddy of Them All. Brady Breeze returned a fumble 31 yards for an early touchdown for the Ducks (12-2). Herbert then made his go-ahead rambling run on the next snap after Breeze forced another fumble in yet another frenetic edition of this venerated bowl game. Oregon held on to cap its Pac-12 championship season with its...

Arizona St, Florida St meet in Sun Bowl without top RBs

Jan 21, 2020

EL PASO, Texas — The top running backs for Arizona State and Florida State won't be around for the Sun Bowl. Sun Devils coach Herm Edwards and interim Seminoles coach Odell Haggins can live with those decisions regardless of their effect on Tuesday's game. “Don't forget that these players that are sitting out actually helped these teams get to bowl games,” Edwards said. "Some people get all sideways. ‘Why isn’t he playing?' It's the way of the world. You don't disrespect them. You don't get mad at them. “I'm hoping they'll show up for the game, stand on the sidelines....

Judge: No slander in Alec Baldwin's comments on parking spat

Jan 21, 2020

NEW YORK — Alec Baldwin didn't slander a man in interviews about a parking dispute that turned physical, a judge has ruled as dueling lawsuits between the actor and the other driver continue. Baldwin's remarks — including claims that Wojciech Cieszkowski's driving was “really fast,” “really aggressive” and made the actor think his wife and son were about to be run over — were "hyperbole" and "rhetorical illustrations," Manhattan judge David B. Cohen wrote Thursday. “They are words of frustration with someone's driving,” not accusations that amount to slander, Cohen wrote. He tossed out Cieszkowski's slander claim, but his assault...

ChillHype brings to you the latest trends, viral, and entertainment news. We create a happy community and keep every Malaysian connected. Let’s chill and catch up with the hype together!

Contact us: sales@chillhype.com